In a press conference on Tuesday, Health Canada announced changes to the system for reporting adverse drug reactions.
“There is important work underway to improve health Canada’s ability to monitor the safety of drugs while they are on the market so that we are able to take appropriate actions to protect Canadian families,” says Health Minister Leona Aglukkaq.
But Health Canada hasn’t announced changes to the process of approving drugs – a process drug experts like Joel Lexchin find concerning. In this excerpt from a 16×9 interview with Lexchin he talks about the drug approval process used by regulators such as the FDA, in the United States, and Health Canada.
Comments